Tag: licensing
-
Gecko-Inspired Adhesive Sticks to Wide Range of Materials
18 April 2014. Materials scientists and biologists at University of Massachusetts in Amherst developed an adhesive technology that attaches heavy loads to a variety of surfaces, yet can still be easily removed and reused. The journal Advanced Materials published yesterday online the work of the team led by polymer scientist Alfred Crosby (paid subscription required).…
-
Daiichi Sankyo, UCSF Partner on Neurodegenerative Disorders
4 April 2014. The pharmaceutical company Daiichi Sankyo in Tokyo and University of California in San Francisco (UCSF) are collaborating on discovering new drugs to treat neurodegenerative conditions such as Alzheimer’s, Parkinson’s, and Creutzfeldt-Jakob disease. While funding amounts were not disclosed, the deal gives Daiichi Sankyo the option to license compounds discovered through the partnership,…
-
Baxter Acquiring Hemophilia Gene-Therapy Biotech Company
3 April 2014. Baxter International, a pharmaceutical and medical products company in Deerfield, Illinois is buying Chatham Therapeutics LLC, a developer of gene therapy to treat hemophilia. Under the agreement, Baxter will acquire outstanding LLC interests in Chatham for $70 million, but future milestone payments are also possible. The acquisition gives Baxter access to all…
-
Patent Awarded for Cancer Antibody Delivery Technology
2 April 2014. The U.S. Patent and Trademark Office awarded a patent for a technology that connects antibodies and cancer drugs to target and deliver treatments directly to tumor cells. Patent number 8,685,383 was awarded yesterday to nine inventors and assigned to Mersana Therapeutics Inc., a biopharmaceutical company in Cambridge, Massachusetts. Timothy Lowinger, Mersana’s chief…
-
Challenge Seeks New Uses for Trial-Tested Drug Compounds
28 March 2014. A new challenge on InnoCentive asks the medical research community for additional uses for drug compounds previously tested in clinical trials by the pharmaceutical company AstraZeneca. The challenge has a prize of $15,000, and a deadline for submissions of 31 May 2014 (free registration required). InnoCentive in Waltham, Massachusetts conducts open-innovation, crowd-sourcing…
-
Engineered Cardiac Tissue Helps Veins Return Blood to Heart
27 March 2014. A pharmacologist at George Washington University in Washington, D.C. developed a technique to produce heart muscle tissue from an individual’s stem cells that helps weak veins return blood back to the heart. The creator of the process, GWU medical school professor Narine Sarvazyan, discussed the technology in a recent online issue of…
-
Light-Activated Coating Kills Bacteria, Even in Dark
25 March 2014. Chemistry researchers at University College London in the U.K. developed a material that when coated on surfaces in the lab can kill bacteria when exposed to light, as well as in total darkness. The team led by UCL chemistry professor Ivan Parkin published its findings online earlier this month in the journal…
-
Bristol-Myers Squibb, Biotech in Cancer Drug Discovery Deal
17 March 2014. Bristol-Myers Squibb, a pharmaceutical company in New York, and Five Prime Therapeutics in South San Francisco, California are collaborating in discovery of cancer immunotherapies. The deal can be worth as much as $350 million to Five Prime Therapeutics, in which Bristol-Myers Squibb will also get a 5 percent stake. Five Prime Therapeutics…
-
Start-Up Company Licenses University Stroke Drug Research
10 March 2014. Zocere Inc. in Albuquerque, New Mexico is licensing a neurological protein from University of New Mexico for development into a drug to protect ischemic stroke victims from extensive brain damage. Financial terms of the deal with the university’s technology transfer office were not disclosed. Nearly 800,000 people in the U.S. have a stroke each…
-
Pharma Alliance Extends Cancer Antibodies to Eye Disorders
4 March 2014. Santen Pharmaceutical Co. in Osaka, Japan is licensing antibodies developed as a cancer therapy by Tracon Pharmaceuticals in San Diego as treatments for eye diseases. Tracon is expected to earn $10 million in an upfront payment from Santen, as well as undisclosed milestone payments and royalties. Tracon develops biologic therapies for cancer,…